Repatha vs Lisinopril: Head-to-Head Efficacy, Women's-Health Differences, and Which Is Right for You

What Is Each Drug Actually Doing in Your Body?

These two medications attack cardiovascular disease through completely separate pathways, so comparing them directly is like comparing a smoke detector to a sprinkler system. You may need both.

How Repatha (Evolocumab) Works

Evolocumab is a monoclonal antibody that blocks PCSK9, a protein that destroys LDL receptors on liver cells. When PCSK9 is blocked, more receptors survive, the liver clears more LDL from your blood, and your LDL-cholesterol can fall by 50-60% from baseline. It does not lower blood pressure. It does not change insulin sensitivity. Its single job is LDL reduction.

How Lisinopril Works

Lisinopril belongs to the ACE inhibitor class. It blocks the conversion of angiotensin I to angiotensin II, which dilates blood vessels, lowers blood pressure, and reduces the workload on your heart. In women with diabetes, it also carries a kidney-protective effect by reducing intraglomerular pressure. It does not change LDL meaningfully.

Because these two drugs operate on entirely different risk factors, there is no scientific rationale for choosing one over the other as a single treatment. A woman with an LDL of 160 mg/dL and a blood pressure of 158/98 mmHg may appropriately be prescribed both.

The Trial Data: What FOURIER and ALLHAT Actually Found

No direct randomized comparison of evolocumab against lisinopril has ever been conducted. Comparing them requires synthesizing two separate trials that enrolled different populations with different endpoints at different points in medical history.

FOURIER (2017): Evolocumab in Established ASCVD

The FOURIER trial, published in the New England England Journal of Medicine in 2017, enrolled 27,564 patients who already had established atherosclerotic cardiovascular disease (ASCVD) and were already on optimized statin therapy. Adding evolocumab reduced the composite primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% relative to placebo over a median follow-up of 2.2 years. The absolute risk reduction was 1.5 percentage points.

Women made up only 27% of the FOURIER population, a representation gap that limits sex-specific conclusions. The direction of benefit was consistent in women, but the trial was not powered to detect statistically significant sex differences. This is the evidence gap women deserve to know about.

ALLHAT (2002): Lisinopril in Hypertensive Adults with Coronary Risk

The ALLHAT trial, published in JAMA in 2002, compared lisinopril, chlorthalidone (a thiazide-type diuretic), and amlodipine (a calcium channel blocker) in 33,357 adults aged 55 and older with hypertension and at least one additional coronary risk factor. For the primary outcome of fatal coronary heart disease or nonfatal MI, lisinopril was equivalent to chlorthalidone. For secondary stroke outcomes, lisinopril performed worse than chlorthalidone, particularly in Black participants. Women made up approximately 47% of ALLHAT, which is one reason the trial remains relevant for female cardiovascular care.

Putting Both Trials Side by Side

| Feature | FOURIER (Evolocumab) | ALLHAT (Lisinopril) | |---|---|---| | Year | 2017 | 2002 | | N | 27,564 | 33,357 | | Population | Established ASCVD on statin | Hypertension plus coronary risk | | Women enrolled | 27% | 47% | | Primary endpoint | MACE composite | Fatal CHD or nonfatal MI | | Relative risk reduction | 15% | Equivalent to comparator | | Key caveat | Women understudied | Worse stroke vs. Chlorthalidone | | Route | Subcutaneous injection | Oral tablet |

Sex-Specific Physiology: Why This Comparison Looks Different for Women

Women are not small men, and cardiovascular risk in women follows a different hormonal timeline than in men.

LDL and the Menopause Transition

LDL-cholesterol tends to rise sharply during perimenopause, often between ages 45 and 55. Estrogen normally upregulates LDL receptors; as estrogen falls, the liver clears LDL less efficiently. In the Study of Women's Health Across the Nation (SWAN), LDL increased by an average of 9 mg/dL in the 12 months surrounding the final menstrual period, a change large enough to shift some women from moderate to high cardiovascular risk. For a postmenopausal woman whose statin therapy is already maximized, evolocumab addresses a real, hormonally driven gap that lisinopril cannot touch.

Blood Pressure and Hormonal Status

Blood pressure in premenopausal women is generally lower than in age-matched men, partly because estrogen promotes vasodilation and sodium excretion. After menopause, that protective effect disappears, and hypertension rates in women catch up to and eventually exceed those in men by age 65. For a perimenopausal woman whose LDL is controlled but whose blood pressure has climbed to 145/90 mmHg, lisinopril is addressing the more pressing, time-sensitive risk factor.

PCOS and Cardiometabolic Risk in Reproductive Years

Women with polycystic ovary syndrome (PCOS) carry elevated cardiovascular risk starting in their 20s and 30s: higher LDL, higher triglycerides, insulin resistance, and a tendency toward hypertension. ACE inhibitors like lisinopril are sometimes chosen in PCOS-related hypertension, but they are absolutely contraindicated in women who are pregnant or attempting pregnancy, which is a critical consideration for reproductive-age women with PCOS who are trying to conceive.

Female-Pattern Metabolic Disease

The INTERHEART study found that in women, the population-attributable fraction of MI from dyslipidemia is slightly lower than in men, while hypertension carries a relatively higher proportional risk. This does not mean LDL management is less important in women; it means both risk factors deserve specific, simultaneous attention rather than a single-drug trade-off.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

This section applies to any woman who is pregnant, breastfeeding, or who could become pregnant while taking either medication.

Lisinopril: A Known Teratogen

Lisinopril is classified as FDA Pregnancy Category D/X depending on trimester. Exposure during the second and third trimesters causes fetal renal tubular dysplasia, oligohydramnios, neonatal skull hypoplasia, and death. These effects are well-documented in humans. Exposure even during the first trimester carries risk, and many experts recommend stopping ACE inhibitors as soon as pregnancy is confirmed or as soon as a patient begins trying to conceive. If you have hypertension and are planning a pregnancy, ask your clinician to switch to a safer alternative such as labetalol, nifedipine, or methyldopa before conception.

Lisinopril passes into breast milk in small amounts. The American Academy of Pediatrics considers it compatible with breastfeeding at usual doses, though monitoring the infant for hypotension is advisable.

Evolocumab: Insufficient Human Data

No adequate human studies exist on evolocumab in pregnancy. Animal studies at exposures approximately 12 times the human dose showed no fetal harm, but that does not establish human safety. The FDA prescribing label advises that evolocumab should be used in pregnancy only if the potential benefit justifies the potential risk. Because LDL-lowering is not urgently required in the short term of a pregnancy, most clinicians and the American College of Cardiology recommend stopping evolocumab before conception and for the duration of breastfeeding. No data exist on transfer into human breast milk.

Women of reproductive age taking evolocumab should use effective contraception, particularly because PCSK9 inhibitor therapy is typically prescribed alongside statins, and statins are independently teratogenic.

Summary Table: Pregnancy and Lactation

| Drug | Pregnancy | Lactation | Pre-Conception Action | |---|---|---|---| | Lisinopril | Contraindicated (2nd/3rd trimester definitively harmful) | Compatible with monitoring | Switch to labetalol, nifedipine, or methyldopa | | Evolocumab | Insufficient data; avoid unless benefit clearly outweighs risk | Unknown; avoid | Stop before conception; ensure statin also stopped |

Side-Effect Profiles: What Women Report Differently

Lisinopril Side Effects in Women

The ACE inhibitor cough, caused by bradykinin accumulation, occurs in approximately 10-15% of white patients but up to 30-40% of Asian patients. Women report this side effect more frequently than men across all ethnicities. If you develop a dry, persistent cough on lisinopril, switching to an angiotensin receptor blocker (ARB) such as losartan achieves similar blood pressure control without the cough.

Hyperkalemia (high potassium) is a real risk, especially in women with chronic kidney disease or who are also taking potassium-sparing diuretics. Angioedema, a rare but life-threatening swelling of the face and throat, occurs more often in Black women and in women over 65.

Evolocumab Side Effects

Injection-site reactions occur in approximately 2-3% of patients. Nasopharyngitis and upper respiratory infections are slightly more common with evolocumab than placebo in trial data. Neurocognitive complaints were raised as a theoretical concern with very low LDL levels; the EBBINGHAUS substudy of FOURIER found no significant difference in cognitive function between evolocumab and placebo over 19 months, a finding that applies equally to women.

Myalgia is not a class effect of PCSK9 inhibitors the way it is with statins, making evolocumab a useful option for women who have statin-associated muscle symptoms.

Who This Is Right For, by Life Stage and Condition

The following framework applies a life-stage lens to help you and your clinician think through which drug or combination fits your current situation.

Reproductive Years (Ages 20-40)

Lisinopril may be appropriate if: You have hypertension secondary to PCOS or chronic kidney disease and you are using reliable contraception. Discontinue as soon as you begin trying to conceive.

Evolocumab is rarely indicated at this stage unless you have familial hypercholesterolemia (FH). Heterozygous FH affects approximately 1 in 250 women and causes LDL levels of 190 mg/dL or higher from birth. For women with FH who cannot tolerate statins or whose LDL remains uncontrolled on maximum statin therapy, evolocumab is a reasonable addition, provided contraception is reliable.

Perimenopause (Ages 40-55, Irregular Cycles)

This is the highest-priority window for reassessing cardiovascular risk in women. LDL commonly rises 10-15 mg/dL across the transition. Blood pressure also tends to climb. A woman who was previously well-controlled on lisinopril alone may now need a statin added, and if she still cannot reach her LDL target, evolocumab becomes a legitimate conversation.

Ask your clinician for a full lipid panel and a 10-year ASCVD risk calculation using the Pooled Cohort Equations at each annual visit during perimenopause.

Postmenopause (No Menstrual Period for 12 Months or More)

Postmenopausal women with established ASCVD (prior MI, stroke, peripheral arterial disease, or coronary revascularization) are the group most directly supported by FOURIER data. If you are already on a maximally tolerated statin and your LDL remains above 70 mg/dL, evolocumab is guideline-supported. The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction endorses PCSK9 inhibitors for this population.

If your blood pressure is also above target despite lifestyle changes, lisinopril (or an ARB if you are cough-prone or of Black African ancestry) should be added. The American Heart Association's 2023 Hypertension Guidelines recommend a target of below 130/80 mmHg for most adults with established cardiovascular disease.

Familial Hypercholesterolemia at Any Age

FH is underdiagnosed in women. Women with FH have a cardiovascular risk roughly 13-fold higher than women without it. Evolocumab is specifically approved for adults with FH and is the drug of choice when statins alone fail to bring LDL below target. Lisinopril addresses a separate risk factor and may also be needed if blood pressure is elevated, but it will not solve the FH problem.

Can You Switch From Repatha to Lisinopril, or Vice Versa?

No. These drugs are not therapeutic substitutes for each other. Switching would mean abandoning control of one major cardiovascular risk factor entirely.

If you are on evolocumab and your cardiologist is suggesting adding lisinopril, that is a sign your blood pressure or kidney protection needs have emerged separately. The two drugs are additive, not alternative.

The only reason a woman might stop evolocumab is cost, pregnancy planning, or a decision made with her clinician that her LDL target has been met sustainably through statin therapy alone. The only reason to stop lisinopril is pregnancy planning, intolerable cough, angioedema, or worsening kidney function with rising creatinine.

Cost, Access, and Insurance Realities for Women

Lisinopril generics cost under $10 per month at most pharmacies, making it one of the most affordable cardiovascular medications available. Most insurance plans cover it at the lowest tier with no prior authorization.

Evolocumab carries a list price of approximately $500 per month before insurance. Commercial insurance plans typically require prior authorization and step therapy, meaning you usually must document that high-intensity statin therapy has failed to bring LDL below the guideline threshold before coverage is approved. Amgen's patient assistance program can bring the out-of-pocket cost to $0 for eligible commercially insured patients.

Women are more likely than men to face insurance gaps due to part-time employment or dependency coverage changes after life events like divorce or a spouse's job loss. If cost is a barrier to evolocumab, ask your clinician whether inclisiran, a small-interfering-RNA PCSK9 inhibitor given twice yearly in-office, offers better coverage through your plan.

The Evidence Gap: What We Still Do Not Know in Women

Women made up only 27% of FOURIER. The sex-stratified subgroup data shows a consistent direction of benefit, but no trial has been powered to detect whether the magnitude of MACE reduction differs by sex, hormonal status, or menopausal stage. The 2021 AHA Scientific Statement on Cardiovascular Disease in Women explicitly named PCSK9 inhibitor data in women as an area requiring further study.

For lisinopril, ALLHAT enrolled 47% women and provides reasonable sex-stratified evidence, but data on postmenopausal-specific outcomes, interactions with hormone therapy, or outcomes in women with PCOS remain sparse. The Menopause Society's 2023 position statement on cardiovascular health notes that antihypertensive therapy evidence in perimenopausal women is largely extrapolated from mixed-sex trials.

This honesty matters: when your clinician makes a recommendation based on FOURIER or ALLHAT data, ask which subgroup your situation most closely resembles.

Practical Questions to Ask Your Clinician Before Starting Either Drug

Use this list at your next appointment:

• What is my 10-year ASCVD risk score, and which risk factor is driving it most?
• Is my LDL above 70 mg/dL (for established ASCVD) or above 100 mg/dL (for high risk without prior events) despite maximum tolerated statin?
• Is my blood pressure above 130/80 mmHg consistently?
• Am I planning a pregnancy in the next 12 months? If so, which medications need to change before I try to conceive?
• Do I have familial hypercholesterolemia, and has that been formally diagnosed or excluded?
• If evolocumab requires prior authorization, what documentation do you need from me to support the appeal?